Among participants in the multiple ascending dose groups, the mean baseline body weight ranged from 88.3 to 99.1 kg
While some GLP-1 options have become available through drugmakers at a discount, the introduction of oral medications has also increased demand, leading to higher costs for employers
Results may be influenced by treatment adherence, lifestyle modifications, individual metabolism, growth and development (in adolescents), underlying health conditions, and emotional wellbeing
The simultaneous activation of these pathways results in a multi-dimensional approach to metabolic regulation
Clinical evidence demonstrates GLP-1 response depends on factors like GLP1R gene variants, baseline insulin resistance, and gastrointestinal sensitivity
Our healthcare team is dedicated to working closely with each patient to assess their unique health needs and determine if Semaglutide GLP-1 is the right choice for them